Truist analyst David MacDonald lowered the firm’s price target on Elevance Health to $560 from $580 and keeps a Buy rating on the shares as part of a broader research note on Healthcare Services names. The analyst cites the recent market moves and updates in multiples following commentary from both UnitedHealth (UNH) and Humana (HUM) around an uptick in utilization, reducing targets in Managed Care and bumping Hospital targets while remaining “broadly bullish” on both groups.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELV:
- Wells Fargo Sees Potential Purchase Window in Managed Care Stocks
- UnitedHealth slides, drags peers on warning of higher medical costs
- 5 Best Healthcare Stocks to Invest in Now, According to Analysts – May 2023
- ‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protection
- Elevance Health upgraded to Overweight from Equal Weight at Morgan Stanley